| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Defibrillators, Implantable | 70 | 2023 | 387 | 9.760 |
Why?
|
| Myocardial Infarction | 130 | 2023 | 1211 | 8.690 |
Why?
|
| Heart Failure | 137 | 2024 | 2326 | 7.890 |
Why?
|
| Cardiology | 64 | 2024 | 362 | 7.800 |
Why?
|
| Registries | 136 | 2024 | 2410 | 7.560 |
Why?
|
| Percutaneous Coronary Intervention | 51 | 2026 | 549 | 6.950 |
Why?
|
| Death, Sudden, Cardiac | 32 | 2021 | 237 | 6.110 |
Why?
|
| Atrial Appendage | 13 | 2024 | 36 | 4.530 |
Why?
|
| Atrial Fibrillation | 29 | 2024 | 558 | 4.140 |
Why?
|
| Primary Prevention | 24 | 2020 | 222 | 3.870 |
Why?
|
| American Heart Association | 45 | 2024 | 358 | 3.380 |
Why?
|
| Cardiac Resynchronization Therapy | 17 | 2023 | 63 | 3.030 |
Why?
|
| United States | 247 | 2026 | 16123 | 3.020 |
Why?
|
| Cardiovascular Diseases | 47 | 2024 | 2191 | 2.890 |
Why?
|
| Hospitalization | 77 | 2024 | 2460 | 2.840 |
Why?
|
| Medicare | 56 | 2024 | 904 | 2.830 |
Why?
|
| Quality of Health Care | 41 | 2024 | 693 | 2.760 |
Why?
|
| Aged | 282 | 2026 | 26215 | 2.610 |
Why?
|
| Stroke | 24 | 2024 | 1271 | 2.520 |
Why?
|
| Ventricular Dysfunction, Left | 18 | 2021 | 394 | 2.480 |
Why?
|
| Coronary Artery Disease | 23 | 2026 | 750 | 2.320 |
Why?
|
| Practice Guidelines as Topic | 35 | 2021 | 1582 | 2.240 |
Why?
|
| Patient Readmission | 31 | 2021 | 772 | 2.200 |
Why?
|
| Hospital Mortality | 51 | 2024 | 1038 | 2.160 |
Why?
|
| Hospitals | 33 | 2024 | 733 | 2.160 |
Why?
|
| Aged, 80 and over | 126 | 2024 | 8346 | 2.120 |
Why?
|
| Secondary Prevention | 14 | 2021 | 251 | 2.100 |
Why?
|
| Humans | 493 | 2026 | 145763 | 2.050 |
Why?
|
| Quality Indicators, Health Care | 27 | 2021 | 336 | 1.980 |
Why?
|
| Quality Assurance, Health Care | 27 | 2015 | 342 | 1.870 |
Why?
|
| Risk Assessment | 63 | 2024 | 3752 | 1.850 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 31 | 2023 | 229 | 1.810 |
Why?
|
| Exercise Test | 18 | 2021 | 630 | 1.810 |
Why?
|
| Societies, Medical | 21 | 2024 | 900 | 1.810 |
Why?
|
| Male | 311 | 2026 | 73003 | 1.780 |
Why?
|
| Treatment Outcome | 112 | 2025 | 11793 | 1.750 |
Why?
|
| Adrenergic beta-Antagonists | 28 | 2018 | 252 | 1.720 |
Why?
|
| Electric Countershock | 11 | 2019 | 126 | 1.710 |
Why?
|
| Female | 311 | 2026 | 79035 | 1.680 |
Why?
|
| Risk Factors | 107 | 2024 | 10917 | 1.650 |
Why?
|
| Sex Factors | 34 | 2020 | 2110 | 1.570 |
Why?
|
| Stroke Volume | 34 | 2024 | 655 | 1.570 |
Why?
|
| Acute Coronary Syndrome | 8 | 2024 | 297 | 1.490 |
Why?
|
| Middle Aged | 178 | 2026 | 36302 | 1.460 |
Why?
|
| Arrhythmias, Cardiac | 10 | 2020 | 356 | 1.420 |
Why?
|
| Anti-Arrhythmia Agents | 7 | 2018 | 144 | 1.400 |
Why?
|
| Cardiac Catheterization | 13 | 2024 | 559 | 1.370 |
Why?
|
| Patient Discharge | 28 | 2023 | 995 | 1.350 |
Why?
|
| Forecasting | 6 | 2022 | 390 | 1.340 |
Why?
|
| China | 43 | 2022 | 273 | 1.340 |
Why?
|
| Electrocardiography | 19 | 2020 | 668 | 1.340 |
Why?
|
| Retrospective Studies | 119 | 2023 | 17325 | 1.320 |
Why?
|
| Coronary Artery Bypass | 12 | 2026 | 268 | 1.290 |
Why?
|
| Acute Kidney Injury | 13 | 2024 | 874 | 1.250 |
Why?
|
| Quality Improvement | 19 | 2024 | 1296 | 1.250 |
Why?
|
| Myocardial Ischemia | 10 | 2019 | 285 | 1.210 |
Why?
|
| Health Status | 20 | 2020 | 835 | 1.210 |
Why?
|
| Coronary Disease | 13 | 2019 | 382 | 1.210 |
Why?
|
| Time Factors | 68 | 2024 | 7133 | 1.170 |
Why?
|
| Practice Patterns, Physicians' | 21 | 2019 | 1372 | 1.140 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 11 | 2022 | 69 | 1.130 |
Why?
|
| Healthcare Disparities | 15 | 2024 | 736 | 1.110 |
Why?
|
| Advisory Committees | 14 | 2021 | 229 | 1.100 |
Why?
|
| Patient Selection | 21 | 2026 | 739 | 1.090 |
Why?
|
| Fee-for-Service Plans | 8 | 2021 | 99 | 1.090 |
Why?
|
| Ventricular Function, Left | 17 | 2022 | 544 | 1.070 |
Why?
|
| Follow-Up Studies | 57 | 2021 | 5428 | 1.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2020 | 444 | 1.020 |
Why?
|
| Home Care Services | 7 | 2019 | 284 | 1.010 |
Why?
|
| Guideline Adherence | 19 | 2020 | 587 | 1.000 |
Why?
|
| Anemia | 9 | 2017 | 191 | 1.000 |
Why?
|
| Decision Support Techniques | 8 | 2021 | 480 | 0.970 |
Why?
|
| Hypertension | 17 | 2022 | 1276 | 0.960 |
Why?
|
| Angina Pectoris | 9 | 2018 | 76 | 0.960 |
Why?
|
| Survival Rate | 38 | 2021 | 2094 | 0.960 |
Why?
|
| Thiazolidinediones | 5 | 2010 | 143 | 0.930 |
Why?
|
| Age Factors | 37 | 2021 | 3346 | 0.930 |
Why?
|
| Myocardial Reperfusion | 8 | 2016 | 56 | 0.920 |
Why?
|
| Cohort Studies | 53 | 2024 | 6032 | 0.920 |
Why?
|
| Hospital Costs | 3 | 2019 | 125 | 0.920 |
Why?
|
| Aspirin | 14 | 2022 | 406 | 0.910 |
Why?
|
| Length of Stay | 14 | 2020 | 1350 | 0.910 |
Why?
|
| Patient Care | 2 | 2020 | 120 | 0.890 |
Why?
|
| Bradycardia | 3 | 2021 | 61 | 0.890 |
Why?
|
| Angioplasty, Balloon, Coronary | 12 | 2012 | 156 | 0.890 |
Why?
|
| Diabetes Mellitus | 17 | 2022 | 1101 | 0.890 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 5 | 2019 | 16 | 0.870 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 6 | 2020 | 18 | 0.870 |
Why?
|
| Clinical Decision-Making | 9 | 2021 | 364 | 0.860 |
Why?
|
| Ambulatory Care | 7 | 2020 | 610 | 0.860 |
Why?
|
| Evidence-Based Medicine | 13 | 2019 | 740 | 0.860 |
Why?
|
| Postoperative Hemorrhage | 5 | 2021 | 105 | 0.850 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2025 | 1751 | 0.840 |
Why?
|
| Coronary Angiography | 12 | 2024 | 328 | 0.840 |
Why?
|
| Quality of Life | 21 | 2020 | 3210 | 0.790 |
Why?
|
| Pacemaker, Artificial | 4 | 2021 | 128 | 0.790 |
Why?
|
| Survival Analysis | 22 | 2021 | 1378 | 0.770 |
Why?
|
| Antihypertensive Agents | 9 | 2022 | 521 | 0.770 |
Why?
|
| Multimorbidity | 2 | 2021 | 65 | 0.770 |
Why?
|
| Insurance, Health | 4 | 2021 | 311 | 0.770 |
Why?
|
| ST Elevation Myocardial Infarction | 7 | 2021 | 64 | 0.750 |
Why?
|
| Disease Management | 10 | 2021 | 653 | 0.750 |
Why?
|
| Hypoglycemic Agents | 15 | 2025 | 1399 | 0.740 |
Why?
|
| Tachycardia, Ventricular | 3 | 2019 | 180 | 0.720 |
Why?
|
| Multivariate Analysis | 32 | 2018 | 1547 | 0.700 |
Why?
|
| Heart Diseases | 7 | 2020 | 341 | 0.700 |
Why?
|
| Myocardial Revascularization | 11 | 2018 | 85 | 0.700 |
Why?
|
| Data Accuracy | 1 | 2022 | 65 | 0.690 |
Why?
|
| Research Report | 7 | 2021 | 86 | 0.690 |
Why?
|
| Incidence | 27 | 2021 | 2933 | 0.690 |
Why?
|
| Text Messaging | 5 | 2025 | 182 | 0.690 |
Why?
|
| Odds Ratio | 22 | 2018 | 1083 | 0.690 |
Why?
|
| Cross-Sectional Studies | 38 | 2023 | 5922 | 0.690 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 4 | 2024 | 26 | 0.680 |
Why?
|
| Creatinine | 13 | 2024 | 515 | 0.680 |
Why?
|
| Social Responsibility | 3 | 2016 | 53 | 0.680 |
Why?
|
| Clinical Trials as Topic | 10 | 2022 | 1062 | 0.660 |
Why?
|
| Radial Artery | 1 | 2021 | 75 | 0.660 |
Why?
|
| Insurance Carriers | 1 | 2021 | 13 | 0.660 |
Why?
|
| Prognosis | 33 | 2024 | 4329 | 0.640 |
Why?
|
| Health Care Costs | 5 | 2019 | 425 | 0.620 |
Why?
|
| Cardiac Output, Low | 6 | 2006 | 53 | 0.620 |
Why?
|
| Hemorrhage | 11 | 2024 | 822 | 0.600 |
Why?
|
| Logistic Models | 25 | 2018 | 2139 | 0.600 |
Why?
|
| Minority Groups | 3 | 2026 | 285 | 0.600 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 268 | 0.590 |
Why?
|
| Prospective Studies | 42 | 2024 | 8075 | 0.580 |
Why?
|
| Hyperglycemia | 9 | 2025 | 379 | 0.570 |
Why?
|
| Cardiovascular Agents | 5 | 2021 | 166 | 0.570 |
Why?
|
| Prostheses and Implants | 2 | 2020 | 137 | 0.560 |
Why?
|
| Spironolactone | 4 | 2022 | 40 | 0.560 |
Why?
|
| Delivery of Health Care | 6 | 2020 | 947 | 0.550 |
Why?
|
| Patient Admission | 11 | 2019 | 220 | 0.540 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2018 | 668 | 0.540 |
Why?
|
| Transcatheter Aortic Valve Replacement | 4 | 2021 | 154 | 0.530 |
Why?
|
| Comorbidity | 26 | 2019 | 1662 | 0.530 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 440 | 0.530 |
Why?
|
| Cardiologists | 1 | 2017 | 45 | 0.520 |
Why?
|
| Databases, Factual | 13 | 2020 | 1491 | 0.520 |
Why?
|
| Drug Prescriptions | 9 | 2018 | 288 | 0.520 |
Why?
|
| Health Policy | 9 | 2017 | 400 | 0.520 |
Why?
|
| Hemoglobins | 7 | 2017 | 386 | 0.510 |
Why?
|
| Predictive Value of Tests | 22 | 2018 | 2123 | 0.490 |
Why?
|
| Research Design | 12 | 2022 | 1139 | 0.490 |
Why?
|
| Cardiac Surgical Procedures | 6 | 2018 | 611 | 0.480 |
Why?
|
| Glomerular Filtration Rate | 8 | 2023 | 765 | 0.480 |
Why?
|
| Echocardiography, Stress | 5 | 2018 | 29 | 0.480 |
Why?
|
| Intra-Aortic Balloon Pumping | 3 | 2021 | 19 | 0.470 |
Why?
|
| Patient Transfer | 5 | 2019 | 211 | 0.470 |
Why?
|
| Chest Pain | 5 | 2020 | 99 | 0.470 |
Why?
|
| Platelet Aggregation Inhibitors | 10 | 2021 | 499 | 0.460 |
Why?
|
| Health Resources | 1 | 2017 | 130 | 0.460 |
Why?
|
| Angina, Unstable | 4 | 2016 | 83 | 0.460 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2025 | 2602 | 0.460 |
Why?
|
| Angiotensin Receptor Antagonists | 8 | 2023 | 115 | 0.450 |
Why?
|
| Diabetic Angiopathies | 5 | 2018 | 267 | 0.450 |
Why?
|
| Blood Pressure | 11 | 2022 | 1782 | 0.440 |
Why?
|
| Benchmarking | 5 | 2021 | 191 | 0.440 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 390 | 0.430 |
Why?
|
| Proportional Hazards Models | 19 | 2019 | 1330 | 0.430 |
Why?
|
| Health Status Disparities | 6 | 2024 | 321 | 0.430 |
Why?
|
| Septal Occluder Device | 1 | 2015 | 37 | 0.430 |
Why?
|
| Machine Learning | 5 | 2021 | 587 | 0.430 |
Why?
|
| Metformin | 5 | 2007 | 329 | 0.430 |
Why?
|
| Cardiomyopathies | 2 | 2015 | 335 | 0.430 |
Why?
|
| Health Services Research | 2 | 2007 | 391 | 0.420 |
Why?
|
| Blood Glucose | 11 | 2025 | 2344 | 0.420 |
Why?
|
| Patient-Centered Care | 7 | 2019 | 547 | 0.410 |
Why?
|
| Mortality | 7 | 2019 | 380 | 0.400 |
Why?
|
| Postoperative Complications | 6 | 2019 | 2977 | 0.390 |
Why?
|
| Torsades de Pointes | 1 | 2013 | 23 | 0.390 |
Why?
|
| Medication Adherence | 8 | 2019 | 540 | 0.390 |
Why?
|
| Heart Function Tests | 4 | 2019 | 59 | 0.390 |
Why?
|
| Narcotics | 1 | 2013 | 58 | 0.390 |
Why?
|
| Equipment Design | 4 | 2017 | 525 | 0.380 |
Why?
|
| Syncope | 1 | 2013 | 56 | 0.380 |
Why?
|
| Shock, Cardiogenic | 5 | 2021 | 65 | 0.380 |
Why?
|
| Hemostasis, Surgical | 1 | 2013 | 25 | 0.380 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2021 | 198 | 0.380 |
Why?
|
| Health Expenditures | 4 | 2019 | 194 | 0.370 |
Why?
|
| Prosthesis Implantation | 4 | 2019 | 156 | 0.360 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 113 | 0.360 |
Why?
|
| Cardiovascular System | 2 | 2024 | 139 | 0.350 |
Why?
|
| Prevalence | 15 | 2022 | 2874 | 0.350 |
Why?
|
| Product Surveillance, Postmarketing | 4 | 2020 | 74 | 0.350 |
Why?
|
| Continuity of Patient Care | 3 | 2013 | 297 | 0.350 |
Why?
|
| Embolism | 2 | 2022 | 48 | 0.350 |
Why?
|
| Warfarin | 6 | 2022 | 179 | 0.350 |
Why?
|
| Comparative Effectiveness Research | 6 | 2019 | 169 | 0.350 |
Why?
|
| Methadone | 1 | 2013 | 123 | 0.350 |
Why?
|
| Risk | 10 | 2015 | 923 | 0.350 |
Why?
|
| Adult | 51 | 2025 | 40872 | 0.350 |
Why?
|
| Drug-Eluting Stents | 3 | 2020 | 88 | 0.350 |
Why?
|
| Acculturation | 1 | 2012 | 55 | 0.350 |
Why?
|
| Hospital Records | 1 | 2011 | 10 | 0.340 |
Why?
|
| Convalescence | 1 | 2011 | 19 | 0.340 |
Why?
|
| Surveys and Questionnaires | 16 | 2021 | 6085 | 0.340 |
Why?
|
| Longitudinal Studies | 12 | 2020 | 2967 | 0.340 |
Why?
|
| Epidemiologic Studies | 2 | 2017 | 68 | 0.330 |
Why?
|
| Employee Performance Appraisal | 1 | 2010 | 6 | 0.330 |
Why?
|
| Professionalism | 2 | 2021 | 26 | 0.330 |
Why?
|
| Patient Education as Topic | 5 | 2019 | 777 | 0.330 |
Why?
|
| Mitral Valve | 2 | 2021 | 95 | 0.330 |
Why?
|
| Chi-Square Distribution | 11 | 2017 | 528 | 0.330 |
Why?
|
| Drug Costs | 2 | 2017 | 117 | 0.330 |
Why?
|
| Morbidity | 6 | 2022 | 322 | 0.330 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2021 | 303 | 0.330 |
Why?
|
| Nursing | 1 | 2010 | 37 | 0.320 |
Why?
|
| Pragmatic Clinical Trials as Topic | 3 | 2025 | 133 | 0.320 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2021 | 68 | 0.310 |
Why?
|
| Heart-Assist Devices | 3 | 2021 | 568 | 0.310 |
Why?
|
| Social Determinants of Health | 2 | 2024 | 309 | 0.310 |
Why?
|
| Kidney Diseases | 3 | 2009 | 426 | 0.310 |
Why?
|
| Severity of Illness Index | 14 | 2020 | 2933 | 0.310 |
Why?
|
| Colorado | 11 | 2021 | 4556 | 0.310 |
Why?
|
| Hospitals, Urban | 7 | 2017 | 142 | 0.300 |
Why?
|
| Outpatients | 7 | 2018 | 447 | 0.300 |
Why?
|
| Peripheral Arterial Disease | 3 | 2010 | 509 | 0.300 |
Why?
|
| Anticoagulants | 9 | 2022 | 748 | 0.300 |
Why?
|
| Healthy Lifestyle | 2 | 2020 | 37 | 0.300 |
Why?
|
| Drug Utilization | 6 | 2015 | 168 | 0.300 |
Why?
|
| Thrombolytic Therapy | 4 | 2016 | 164 | 0.300 |
Why?
|
| Pneumonia | 5 | 2017 | 636 | 0.290 |
Why?
|
| Contrast Media | 6 | 2024 | 497 | 0.290 |
Why?
|
| Medicine, Chinese Traditional | 2 | 2019 | 8 | 0.290 |
Why?
|
| Thromboembolism | 2 | 2022 | 129 | 0.290 |
Why?
|
| Cost Savings | 2 | 2019 | 86 | 0.280 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2019 | 24 | 0.280 |
Why?
|
| Health Literacy | 1 | 2011 | 186 | 0.280 |
Why?
|
| Health Status Indicators | 4 | 2020 | 167 | 0.280 |
Why?
|
| Water-Electrolyte Balance | 2 | 2007 | 37 | 0.280 |
Why?
|
| Device Approval | 2 | 2020 | 19 | 0.280 |
Why?
|
| Ischemic Attack, Transient | 2 | 2022 | 71 | 0.270 |
Why?
|
| Exercise Tolerance | 2 | 2008 | 283 | 0.270 |
Why?
|
| Clinical Competence | 4 | 2017 | 1247 | 0.270 |
Why?
|
| Heart Rate | 5 | 2021 | 856 | 0.270 |
Why?
|
| Radiology | 1 | 2010 | 174 | 0.270 |
Why?
|
| Sex Distribution | 5 | 2017 | 388 | 0.270 |
Why?
|
| Physicians | 5 | 2024 | 956 | 0.270 |
Why?
|
| Diagnostic Imaging | 5 | 2013 | 337 | 0.270 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2018 | 50 | 0.270 |
Why?
|
| Cause of Death | 6 | 2020 | 471 | 0.270 |
Why?
|
| Ezetimibe | 2 | 2018 | 24 | 0.270 |
Why?
|
| Fluorobenzenes | 1 | 2007 | 17 | 0.270 |
Why?
|
| Bundle-Branch Block | 4 | 2017 | 37 | 0.260 |
Why?
|
| Nurses, Community Health | 2 | 2019 | 38 | 0.260 |
Why?
|
| Hospitals, Veterans | 3 | 2016 | 258 | 0.260 |
Why?
|
| Survivors | 3 | 2012 | 523 | 0.260 |
Why?
|
| Hyperkalemia | 4 | 2016 | 36 | 0.250 |
Why?
|
| Emergency Service, Hospital | 6 | 2020 | 2383 | 0.250 |
Why?
|
| Hospitals, Low-Volume | 2 | 2024 | 26 | 0.250 |
Why?
|
| Systole | 5 | 2013 | 181 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2016 | 971 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 1420 | 0.250 |
Why?
|
| Epidemiologic Research Design | 1 | 2006 | 29 | 0.250 |
Why?
|
| Hospitals, High-Volume | 2 | 2024 | 50 | 0.240 |
Why?
|
| Attitude of Health Personnel | 3 | 2012 | 1197 | 0.240 |
Why?
|
| Coronary Vessels | 2 | 2019 | 246 | 0.240 |
Why?
|
| Inpatients | 8 | 2014 | 553 | 0.240 |
Why?
|
| Propensity Score | 7 | 2020 | 377 | 0.230 |
Why?
|
| Consensus | 5 | 2024 | 479 | 0.230 |
Why?
|
| Thoracic Surgery | 4 | 2021 | 143 | 0.220 |
Why?
|
| Cholesterol, LDL | 5 | 2018 | 360 | 0.220 |
Why?
|
| Echocardiography | 5 | 2019 | 648 | 0.220 |
Why?
|
| Contraindications | 8 | 2015 | 90 | 0.220 |
Why?
|
| Health Care Reform | 2 | 2018 | 109 | 0.220 |
Why?
|
| Troponin | 3 | 2017 | 50 | 0.220 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 178 | 0.220 |
Why?
|
| Prosthesis Design | 3 | 2016 | 356 | 0.220 |
Why?
|
| Antithrombins | 2 | 2017 | 71 | 0.220 |
Why?
|
| Bibliometrics | 2 | 2016 | 66 | 0.220 |
Why?
|
| Exercise | 5 | 2019 | 2205 | 0.220 |
Why?
|
| Monitoring, Physiologic | 3 | 2017 | 289 | 0.210 |
Why?
|
| Data Collection | 5 | 2017 | 643 | 0.210 |
Why?
|
| Efficiency, Organizational | 3 | 2018 | 141 | 0.210 |
Why?
|
| Polypharmacy | 2 | 2015 | 94 | 0.210 |
Why?
|
| Hospitals, Rural | 4 | 2017 | 49 | 0.210 |
Why?
|
| Acute Disease | 11 | 2019 | 1036 | 0.210 |
Why?
|
| Income | 3 | 2020 | 203 | 0.210 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2015 | 38 | 0.210 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2024 | 71 | 0.210 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2015 | 63 | 0.200 |
Why?
|
| Heart Conduction System | 3 | 2015 | 96 | 0.200 |
Why?
|
| Noncommunicable Diseases | 1 | 2024 | 21 | 0.200 |
Why?
|
| Pyrimidines | 1 | 2007 | 530 | 0.200 |
Why?
|
| Patient Care Planning | 1 | 2025 | 170 | 0.200 |
Why?
|
| Confidence Intervals | 4 | 2014 | 330 | 0.200 |
Why?
|
| Sulfonamides | 1 | 2007 | 583 | 0.200 |
Why?
|
| Telemedicine | 4 | 2025 | 966 | 0.200 |
Why?
|
| Time-to-Treatment | 4 | 2019 | 251 | 0.200 |
Why?
|
| Coronary Care Units | 3 | 2015 | 27 | 0.200 |
Why?
|
| Professional Practice Gaps | 2 | 2020 | 15 | 0.190 |
Why?
|
| Stents | 5 | 2016 | 564 | 0.190 |
Why?
|
| Cross Infection | 2 | 2024 | 260 | 0.190 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2020 | 28 | 0.190 |
Why?
|
| Treatment Refusal | 3 | 2008 | 99 | 0.190 |
Why?
|
| Periodicals as Topic | 2 | 2016 | 209 | 0.190 |
Why?
|
| Referral and Consultation | 5 | 2017 | 868 | 0.190 |
Why?
|
| Thiazoles | 1 | 2003 | 142 | 0.180 |
Why?
|
| Canada | 6 | 2026 | 432 | 0.180 |
Why?
|
| Skilled Nursing Facilities | 2 | 2017 | 152 | 0.180 |
Why?
|
| Computed Tomography Angiography | 2 | 2020 | 146 | 0.180 |
Why?
|
| Pericardial Effusion | 1 | 2022 | 22 | 0.180 |
Why?
|
| Biomarkers | 15 | 2025 | 4302 | 0.180 |
Why?
|
| Renal Insufficiency | 1 | 2004 | 172 | 0.180 |
Why?
|
| Biomedical Research | 1 | 2008 | 719 | 0.180 |
Why?
|
| Technology Transfer | 1 | 2021 | 9 | 0.170 |
Why?
|
| Primary Health Care | 3 | 2025 | 1737 | 0.170 |
Why?
|
| Culturally Competent Care | 2 | 2019 | 72 | 0.170 |
Why?
|
| Catheter Ablation | 2 | 2017 | 355 | 0.170 |
Why?
|
| Sex Characteristics | 2 | 2022 | 789 | 0.170 |
Why?
|
| Accreditation | 2 | 2020 | 101 | 0.170 |
Why?
|
| Hypercholesterolemia | 1 | 2022 | 95 | 0.170 |
Why?
|
| Administrative Personnel | 2 | 2019 | 33 | 0.170 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2019 | 104 | 0.170 |
Why?
|
| Models, Statistical | 5 | 2019 | 672 | 0.170 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 217 | 0.170 |
Why?
|
| Mass Screening | 4 | 2019 | 1361 | 0.170 |
Why?
|
| Patient Participation | 2 | 2016 | 446 | 0.170 |
Why?
|
| Physician-Patient Relations | 3 | 2014 | 588 | 0.160 |
Why?
|
| Manufacturing Industry | 1 | 2020 | 6 | 0.160 |
Why?
|
| Fibrinolytic Agents | 4 | 2022 | 297 | 0.160 |
Why?
|
| Long Term Adverse Effects | 1 | 2020 | 13 | 0.160 |
Why?
|
| Creatine Kinase, MB Form | 2 | 2017 | 6 | 0.160 |
Why?
|
| Decision Making | 7 | 2016 | 982 | 0.160 |
Why?
|
| Geographic Mapping | 1 | 2020 | 26 | 0.160 |
Why?
|
| Ethics, Medical | 1 | 2021 | 91 | 0.160 |
Why?
|
| Recovery of Function | 6 | 2020 | 716 | 0.160 |
Why?
|
| Prosthesis Failure | 2 | 2018 | 125 | 0.160 |
Why?
|
| Social Class | 3 | 2019 | 264 | 0.160 |
Why?
|
| Managed Care Programs | 2 | 2011 | 140 | 0.160 |
Why?
|
| Benzoxazoles | 1 | 2020 | 20 | 0.150 |
Why?
|
| Bacteremia | 2 | 2021 | 222 | 0.150 |
Why?
|
| Femoral Artery | 1 | 2021 | 190 | 0.150 |
Why?
|
| Young Adult | 12 | 2022 | 14251 | 0.150 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2010 | 84 | 0.150 |
Why?
|
| New York | 2 | 2017 | 128 | 0.150 |
Why?
|
| Amyloidosis | 1 | 2020 | 45 | 0.150 |
Why?
|
| Neprilysin | 1 | 2020 | 47 | 0.150 |
Why?
|
| Body Mass Index | 5 | 2021 | 2447 | 0.150 |
Why?
|
| Reoperation | 2 | 2020 | 637 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 2028 | 0.150 |
Why?
|
| International Cooperation | 2 | 2018 | 197 | 0.150 |
Why?
|
| Health Care Surveys | 5 | 2019 | 536 | 0.150 |
Why?
|
| Self Care | 2 | 2019 | 392 | 0.150 |
Why?
|
| Models, Economic | 1 | 2019 | 62 | 0.150 |
Why?
|
| Digoxin | 1 | 2019 | 27 | 0.150 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 390 | 0.150 |
Why?
|
| Reproducibility of Results | 9 | 2021 | 3416 | 0.150 |
Why?
|
| Reimbursement Mechanisms | 1 | 2019 | 79 | 0.150 |
Why?
|
| Information Storage and Retrieval | 1 | 2020 | 123 | 0.150 |
Why?
|
| Cardiology Service, Hospital | 1 | 2019 | 29 | 0.140 |
Why?
|
| Multiple Chronic Conditions | 1 | 2019 | 34 | 0.140 |
Why?
|
| Thinness | 1 | 2019 | 100 | 0.140 |
Why?
|
| Vena Cava Filters | 2 | 2018 | 64 | 0.140 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 208 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 221 | 0.140 |
Why?
|
| Return to Work | 1 | 2018 | 21 | 0.140 |
Why?
|
| Disease Progression | 6 | 2013 | 2865 | 0.140 |
Why?
|
| Anticholesteremic Agents | 2 | 2017 | 155 | 0.140 |
Why?
|
| Medical Records | 5 | 2016 | 192 | 0.140 |
Why?
|
| Frailty | 1 | 2022 | 205 | 0.140 |
Why?
|
| Nursing Staff | 1 | 2019 | 41 | 0.140 |
Why?
|
| Nutrition Surveys | 4 | 2023 | 279 | 0.140 |
Why?
|
| Fraud | 1 | 2018 | 11 | 0.140 |
Why?
|
| Equipment Safety | 2 | 2015 | 38 | 0.140 |
Why?
|
| Regression Analysis | 6 | 2017 | 1001 | 0.140 |
Why?
|
| Drug Utilization Review | 2 | 2012 | 61 | 0.140 |
Why?
|
| Medical Record Linkage | 2 | 2015 | 69 | 0.140 |
Why?
|
| Medical Overuse | 1 | 2018 | 30 | 0.140 |
Why?
|
| Transitional Care | 1 | 2018 | 45 | 0.140 |
Why?
|
| Ticlopidine | 2 | 2015 | 52 | 0.140 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2018 | 48 | 0.130 |
Why?
|
| Liability, Legal | 1 | 2018 | 42 | 0.130 |
Why?
|
| Coronary Stenosis | 1 | 2018 | 40 | 0.130 |
Why?
|
| Data Mining | 1 | 2018 | 113 | 0.130 |
Why?
|
| Dabigatran | 1 | 2017 | 30 | 0.130 |
Why?
|
| Health Services Accessibility | 4 | 2019 | 1101 | 0.130 |
Why?
|
| Subacute Care | 1 | 2018 | 84 | 0.130 |
Why?
|
| Socioeconomic Factors | 7 | 2019 | 1327 | 0.130 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2008 | 124 | 0.130 |
Why?
|
| Arteriosclerosis | 1 | 2017 | 83 | 0.130 |
Why?
|
| Patient Care Management | 1 | 2017 | 56 | 0.130 |
Why?
|
| Heart Arrest | 3 | 2021 | 411 | 0.130 |
Why?
|
| Depression | 6 | 2012 | 1557 | 0.130 |
Why?
|
| Health Surveys | 3 | 2015 | 520 | 0.130 |
Why?
|
| Postoperative Care | 4 | 2013 | 286 | 0.130 |
Why?
|
| Vaccines | 1 | 2022 | 389 | 0.130 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 269 | 0.130 |
Why?
|
| Telemetry | 1 | 2017 | 40 | 0.130 |
Why?
|
| Simvastatin | 1 | 2017 | 59 | 0.130 |
Why?
|
| Patient Preference | 2 | 2026 | 223 | 0.130 |
Why?
|
| Pulmonary Embolism | 2 | 2018 | 241 | 0.130 |
Why?
|
| Elective Surgical Procedures | 1 | 2018 | 203 | 0.130 |
Why?
|
| Recurrence | 3 | 2018 | 1139 | 0.120 |
Why?
|
| Educational Status | 1 | 2019 | 470 | 0.120 |
Why?
|
| Insurance Coverage | 1 | 2018 | 244 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2018 | 184 | 0.120 |
Why?
|
| Policy | 2 | 2022 | 149 | 0.120 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2015 | 4 | 0.120 |
Why?
|
| Veterans Health | 1 | 2017 | 190 | 0.110 |
Why?
|
| Documentation | 1 | 2017 | 199 | 0.110 |
Why?
|
| Factor Xa Inhibitors | 1 | 2017 | 194 | 0.110 |
Why?
|
| Pyridones | 1 | 2017 | 209 | 0.110 |
Why?
|
| Blood Coagulation | 1 | 2017 | 274 | 0.110 |
Why?
|
| Equipment and Supplies | 1 | 2015 | 37 | 0.110 |
Why?
|
| Kidney | 3 | 2023 | 1496 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 498 | 0.110 |
Why?
|
| Clinical Chemistry Tests | 1 | 2015 | 6 | 0.110 |
Why?
|
| Obesity | 3 | 2019 | 3118 | 0.110 |
Why?
|
| Sepsis | 1 | 2021 | 664 | 0.110 |
Why?
|
| Drug Substitution | 1 | 2015 | 63 | 0.110 |
Why?
|
| Blood Vessels | 1 | 2016 | 167 | 0.110 |
Why?
|
| Rivaroxaban | 1 | 2017 | 271 | 0.110 |
Why?
|
| Mandatory Reporting | 1 | 2015 | 45 | 0.110 |
Why?
|
| Weight Reduction Programs | 1 | 2016 | 140 | 0.110 |
Why?
|
| Drug Monitoring | 2 | 2021 | 401 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 120 | 0.110 |
Why?
|
| Japan | 3 | 2021 | 149 | 0.110 |
Why?
|
| Qualitative Research | 3 | 2019 | 1683 | 0.110 |
Why?
|
| Linear Models | 4 | 2017 | 849 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2017 | 779 | 0.100 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2015 | 79 | 0.100 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 256 | 0.100 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2014 | 24 | 0.100 |
Why?
|
| Aortic Valve | 1 | 2017 | 364 | 0.100 |
Why?
|
| Patient Compliance | 3 | 2008 | 588 | 0.100 |
Why?
|
| Preventive Health Services | 1 | 2015 | 153 | 0.100 |
Why?
|
| Single-Blind Method | 3 | 2019 | 318 | 0.100 |
Why?
|
| Adolescent | 9 | 2021 | 22573 | 0.100 |
Why?
|
| Urination Disorders | 1 | 2013 | 15 | 0.100 |
Why?
|
| Endarterectomy, Carotid | 1 | 2014 | 64 | 0.100 |
Why?
|
| Residence Characteristics | 5 | 2015 | 375 | 0.100 |
Why?
|
| Community Health Services | 2 | 2013 | 231 | 0.100 |
Why?
|
| Workplace | 1 | 2015 | 272 | 0.100 |
Why?
|
| Pulmonary Valve | 1 | 2015 | 102 | 0.100 |
Why?
|
| Administration, Oral | 5 | 2017 | 867 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2017 | 517 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 328 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 2014 | 125 | 0.100 |
Why?
|
| Ventricular Premature Complexes | 1 | 2013 | 37 | 0.100 |
Why?
|
| Myocardium | 2 | 2015 | 935 | 0.100 |
Why?
|
| Patient Safety | 2 | 2018 | 356 | 0.090 |
Why?
|
| Lung Transplantation | 1 | 2016 | 332 | 0.090 |
Why?
|
| Cardiac Rehabilitation | 2 | 2017 | 46 | 0.090 |
Why?
|
| Body Weight | 1 | 2017 | 972 | 0.090 |
Why?
|
| Hirudins | 1 | 2013 | 53 | 0.090 |
Why?
|
| Gait | 1 | 2016 | 312 | 0.090 |
Why?
|
| Observation | 1 | 2012 | 54 | 0.090 |
Why?
|
| ROC Curve | 3 | 2019 | 618 | 0.090 |
Why?
|
| Pacific States | 1 | 2012 | 7 | 0.090 |
Why?
|
| New England | 1 | 2012 | 37 | 0.090 |
Why?
|
| Communication | 1 | 2019 | 977 | 0.090 |
Why?
|
| Poisson Distribution | 2 | 2012 | 78 | 0.090 |
Why?
|
| Health Maintenance Organizations | 1 | 2012 | 105 | 0.090 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 1043 | 0.090 |
Why?
|
| Erythrocyte Indices | 1 | 2012 | 33 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 5 | 2017 | 644 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2016 | 944 | 0.090 |
Why?
|
| Patient Satisfaction | 2 | 2025 | 712 | 0.090 |
Why?
|
| Reimbursement, Incentive | 2 | 2015 | 42 | 0.090 |
Why?
|
| Activities of Daily Living | 3 | 2012 | 444 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 883 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 173 | 0.090 |
Why?
|
| Drug Resistance | 1 | 2012 | 145 | 0.090 |
Why?
|
| Pregnancy | 2 | 2022 | 7215 | 0.090 |
Why?
|
| National Health Programs | 2 | 2015 | 23 | 0.090 |
Why?
|
| Rural Population | 4 | 2019 | 661 | 0.090 |
Why?
|
| Phlebotomy | 1 | 2011 | 22 | 0.090 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 164 | 0.080 |
Why?
|
| Hospitals, Teaching | 3 | 2021 | 121 | 0.080 |
Why?
|
| Social Environment | 1 | 2013 | 252 | 0.080 |
Why?
|
| Angioplasty | 1 | 2011 | 50 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2012 | 222 | 0.080 |
Why?
|
| Clinical Medicine | 1 | 2011 | 26 | 0.080 |
Why?
|
| Laboratories, Hospital | 1 | 2011 | 14 | 0.080 |
Why?
|
| Independent Living | 1 | 2012 | 116 | 0.080 |
Why?
|
| Carotid Artery Diseases | 1 | 2011 | 70 | 0.080 |
Why?
|
| Opiate Substitution Treatment | 1 | 2013 | 189 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2012 | 328 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2026 | 1897 | 0.080 |
Why?
|
| Physical Fitness | 1 | 2012 | 207 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2012 | 501 | 0.080 |
Why?
|
| Eligibility Determination | 3 | 2017 | 72 | 0.080 |
Why?
|
| Aftercare | 2 | 2022 | 222 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 562 | 0.080 |
Why?
|
| Sickness Impact Profile | 2 | 2012 | 62 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1505 | 0.080 |
Why?
|
| Diuretics | 2 | 2012 | 68 | 0.080 |
Why?
|
| Potassium | 2 | 2013 | 152 | 0.080 |
Why?
|
| Depressive Disorder | 2 | 2010 | 374 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 2016 | 680 | 0.080 |
Why?
|
| Caregivers | 1 | 2019 | 1074 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 1368 | 0.080 |
Why?
|
| Asia | 2 | 2020 | 70 | 0.070 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2013 | 339 | 0.070 |
Why?
|
| Poverty | 1 | 2013 | 529 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2013 | 696 | 0.070 |
Why?
|
| Cost of Illness | 3 | 2015 | 324 | 0.070 |
Why?
|
| Probability | 1 | 2010 | 308 | 0.070 |
Why?
|
| Overweight | 2 | 2019 | 614 | 0.070 |
Why?
|
| Public Health Informatics | 1 | 2008 | 10 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2012 | 430 | 0.070 |
Why?
|
| Prosthesis-Related Infections | 1 | 2010 | 98 | 0.070 |
Why?
|
| Cardiotonic Agents | 2 | 2013 | 94 | 0.070 |
Why?
|
| Observational Studies as Topic | 2 | 2020 | 134 | 0.070 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2008 | 82 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 684 | 0.070 |
Why?
|
| Urban Population | 3 | 2017 | 494 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2010 | 252 | 0.070 |
Why?
|
| Rosuvastatin Calcium | 1 | 2007 | 21 | 0.070 |
Why?
|
| California | 2 | 2006 | 473 | 0.070 |
Why?
|
| Internal Medicine | 1 | 2010 | 279 | 0.070 |
Why?
|
| Atrial Flutter | 1 | 2008 | 47 | 0.060 |
Why?
|
| Proprotein Convertase 9 | 2 | 2018 | 87 | 0.060 |
Why?
|
| Rehabilitation | 1 | 2007 | 20 | 0.060 |
Why?
|
| Palliative Care | 2 | 2007 | 1022 | 0.060 |
Why?
|
| Certificate of Need | 1 | 2007 | 2 | 0.060 |
Why?
|
| Reimbursement, Disproportionate Share | 1 | 2007 | 1 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2017 | 3937 | 0.060 |
Why?
|
| Retreatment | 2 | 2020 | 80 | 0.060 |
Why?
|
| Protective Factors | 2 | 2018 | 99 | 0.060 |
Why?
|
| Insulin | 3 | 2013 | 2516 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 288 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2007 | 360 | 0.060 |
Why?
|
| Reperfusion | 1 | 2006 | 54 | 0.060 |
Why?
|
| Renal Dialysis | 3 | 2016 | 466 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 2 | 2017 | 105 | 0.060 |
Why?
|
| Blood Urea Nitrogen | 1 | 2006 | 53 | 0.060 |
Why?
|
| Edema | 1 | 2007 | 125 | 0.060 |
Why?
|
| Terminology as Topic | 2 | 2024 | 259 | 0.060 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2006 | 154 | 0.060 |
Why?
|
| Interviews as Topic | 3 | 2021 | 916 | 0.060 |
Why?
|
| Vulnerable Populations | 1 | 2007 | 176 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 222 | 0.060 |
Why?
|
| Body Temperature | 1 | 2006 | 227 | 0.060 |
Why?
|
| International Classification of Diseases | 2 | 2021 | 150 | 0.050 |
Why?
|
| Endocarditis | 2 | 2010 | 40 | 0.050 |
Why?
|
| Opioid-Related Disorders | 1 | 2013 | 605 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2005 | 109 | 0.050 |
Why?
|
| Heart Valves | 1 | 2005 | 44 | 0.050 |
Why?
|
| Atrial Function, Left | 1 | 2024 | 9 | 0.050 |
Why?
|
| Specialization | 1 | 2005 | 137 | 0.050 |
Why?
|
| Appointments and Schedules | 1 | 2025 | 96 | 0.050 |
Why?
|
| Hospital-Physician Relations | 1 | 2024 | 4 | 0.050 |
Why?
|
| Hypoglycemia | 1 | 2009 | 480 | 0.050 |
Why?
|
| Motivation | 2 | 2019 | 602 | 0.050 |
Why?
|
| Cultural Characteristics | 1 | 2004 | 69 | 0.050 |
Why?
|
| Databases as Topic | 3 | 2010 | 71 | 0.050 |
Why?
|
| Medicine | 1 | 2005 | 125 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 413 | 0.050 |
Why?
|
| Weight Gain | 1 | 2007 | 561 | 0.050 |
Why?
|
| Medication Therapy Management | 2 | 2017 | 72 | 0.050 |
Why?
|
| Research | 2 | 2008 | 431 | 0.050 |
Why?
|
| Ibuprofen | 1 | 2003 | 87 | 0.050 |
Why?
|
| Michigan | 2 | 2015 | 134 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 782 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 2770 | 0.050 |
Why?
|
| Health Services Needs and Demand | 2 | 2016 | 280 | 0.050 |
Why?
|
| Health Promotion | 1 | 2008 | 775 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2026 | 1115 | 0.040 |
Why?
|
| Weight Loss | 1 | 2007 | 859 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2003 | 225 | 0.040 |
Why?
|
| Diagnosis-Related Groups | 1 | 2021 | 35 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1300 | 0.040 |
Why?
|
| Maryland | 1 | 2021 | 67 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 138 | 0.040 |
Why?
|
| Reminder Systems | 1 | 2022 | 140 | 0.040 |
Why?
|
| Smoking Cessation | 2 | 2020 | 441 | 0.040 |
Why?
|
| Assisted Circulation | 1 | 2021 | 26 | 0.040 |
Why?
|
| Medical Device Legislation | 1 | 2020 | 3 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 346 | 0.040 |
Why?
|
| Standard of Care | 1 | 2021 | 81 | 0.040 |
Why?
|
| Decision Trees | 2 | 2016 | 78 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2020 | 138 | 0.040 |
Why?
|
| Matched-Pair Analysis | 1 | 2020 | 37 | 0.040 |
Why?
|
| Coronary Thrombosis | 1 | 2020 | 25 | 0.040 |
Why?
|
| Latin America | 1 | 2020 | 96 | 0.040 |
Why?
|
| Coronary Restenosis | 1 | 2020 | 22 | 0.040 |
Why?
|
| Family Practice | 1 | 2004 | 407 | 0.040 |
Why?
|
| Medicaid | 2 | 2017 | 467 | 0.040 |
Why?
|
| Argentina | 1 | 2019 | 30 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2022 | 3634 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2008 | 1169 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 179 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2015 | 920 | 0.040 |
Why?
|
| Evidence-Based Practice | 2 | 2013 | 231 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 1270 | 0.040 |
Why?
|
| Health Personnel | 2 | 2018 | 757 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2019 | 85 | 0.040 |
Why?
|
| Health Communication | 1 | 2019 | 53 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 1957 | 0.040 |
Why?
|
| United States Government Agencies | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2020 | 219 | 0.030 |
Why?
|
| Retirement | 1 | 2018 | 35 | 0.030 |
Why?
|
| Clinical Audit | 1 | 2018 | 14 | 0.030 |
Why?
|
| Hospital Charges | 1 | 2018 | 46 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2006 | 1244 | 0.030 |
Why?
|
| Sample Size | 1 | 2018 | 121 | 0.030 |
Why?
|
| Malpractice | 1 | 2018 | 44 | 0.030 |
Why?
|
| Internationality | 1 | 2018 | 156 | 0.030 |
Why?
|
| F Factor | 1 | 2017 | 4 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 343 | 0.030 |
Why?
|
| Puerperal Disorders | 1 | 2018 | 36 | 0.030 |
Why?
|
| Health Facility Size | 1 | 2017 | 13 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 172 | 0.030 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2018 | 85 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 83 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2021 | 409 | 0.030 |
Why?
|
| Drug Approval | 1 | 2017 | 93 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2017 | 98 | 0.030 |
Why?
|
| Arabidopsis Proteins | 1 | 2017 | 76 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 2017 | 80 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 368 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2010 | 380 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2008 | 283 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 618 | 0.030 |
Why?
|
| Algorithms | 2 | 2015 | 1850 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 291 | 0.030 |
Why?
|
| Spain | 1 | 2015 | 50 | 0.030 |
Why?
|
| Cooperative Behavior | 2 | 2009 | 463 | 0.030 |
Why?
|
| Health Care Sector | 1 | 2015 | 26 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 56 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1995 | 13 | 0.030 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 1995 | 5 | 0.030 |
Why?
|
| Hospital Bed Capacity | 1 | 2015 | 27 | 0.030 |
Why?
|
| Industry | 1 | 2015 | 42 | 0.030 |
Why?
|
| Classification | 1 | 2015 | 44 | 0.030 |
Why?
|
| Health Care Rationing | 1 | 2015 | 56 | 0.030 |
Why?
|
| Urban Health Services | 1 | 2015 | 69 | 0.030 |
Why?
|
| Life Style | 1 | 2017 | 486 | 0.030 |
Why?
|
| Conflict of Interest | 1 | 2015 | 54 | 0.030 |
Why?
|
| Journal Impact Factor | 1 | 2015 | 29 | 0.030 |
Why?
|
| Operative Time | 1 | 2015 | 181 | 0.030 |
Why?
|
| Health Behavior | 2 | 2015 | 791 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2015 | 136 | 0.030 |
Why?
|
| Peer Review, Research | 1 | 2015 | 36 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2015 | 132 | 0.030 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2015 | 61 | 0.030 |
Why?
|
| Access to Information | 1 | 2015 | 48 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3915 | 0.030 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1995 | 68 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 251 | 0.030 |
Why?
|
| Academic Medical Centers | 2 | 2009 | 554 | 0.030 |
Why?
|
| Age Distribution | 2 | 2005 | 404 | 0.030 |
Why?
|
| Markov Chains | 2 | 2009 | 132 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 2064 | 0.030 |
Why?
|
| Ischemia | 1 | 2018 | 422 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2005 | 1812 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 280 | 0.030 |
Why?
|
| Physical Examination | 1 | 2015 | 244 | 0.030 |
Why?
|
| Drug Hypersensitivity | 1 | 2015 | 90 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 1995 | 113 | 0.030 |
Why?
|
| Ownership | 1 | 2015 | 115 | 0.030 |
Why?
|
| Jejunum | 1 | 1994 | 37 | 0.030 |
Why?
|
| Rural Health Services | 1 | 2015 | 138 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2014 | 91 | 0.020 |
Why?
|
| Age of Onset | 1 | 2015 | 557 | 0.020 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2013 | 17 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 1428 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 287 | 0.020 |
Why?
|
| Observer Variation | 1 | 2014 | 357 | 0.020 |
Why?
|
| Research Personnel | 1 | 2015 | 185 | 0.020 |
Why?
|
| Intestinal Absorption | 1 | 1994 | 103 | 0.020 |
Why?
|
| Pandemics | 1 | 2021 | 1711 | 0.020 |
Why?
|
| Triage | 1 | 2015 | 250 | 0.020 |
Why?
|
| Food | 1 | 1994 | 150 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2012 | 71 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 843 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2013 | 115 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 740 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 428 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2015 | 719 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1997 | 1118 | 0.020 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2013 | 103 | 0.020 |
Why?
|
| Medical Audit | 1 | 2012 | 77 | 0.020 |
Why?
|
| Electrodes, Implanted | 1 | 2013 | 114 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2012 | 55 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1995 | 258 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2015 | 355 | 0.020 |
Why?
|
| Foundations | 1 | 2011 | 27 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 992 | 0.020 |
Why?
|
| Dementia | 1 | 2015 | 328 | 0.020 |
Why?
|
| Self Report | 1 | 2015 | 876 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2015 | 578 | 0.020 |
Why?
|
| Ankle Brachial Index | 1 | 2010 | 41 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2017 | 782 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 1003 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 24 | 0.020 |
Why?
|
| Patients | 1 | 2011 | 183 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2010 | 67 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2010 | 80 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 1477 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 2000 | 0.020 |
Why?
|
| Life Tables | 1 | 2009 | 21 | 0.020 |
Why?
|
| Aortic Diseases | 1 | 2010 | 125 | 0.020 |
Why?
|
| Leadership | 1 | 2013 | 402 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 74 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2008 | 103 | 0.020 |
Why?
|
| Regional Health Planning | 1 | 2008 | 8 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1994 | 675 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1995 | 981 | 0.020 |
Why?
|
| Public Health | 1 | 2013 | 574 | 0.020 |
Why?
|
| Drug Labeling | 1 | 2007 | 37 | 0.020 |
Why?
|
| Time and Motion Studies | 1 | 2007 | 28 | 0.020 |
Why?
|
| Vitamin E | 1 | 1988 | 125 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 1988 | 109 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2015 | 1202 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2013 | 924 | 0.020 |
Why?
|
| Prospective Payment System | 1 | 2007 | 15 | 0.020 |
Why?
|
| Fees, Medical | 1 | 2006 | 9 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2008 | 145 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 3170 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2008 | 107 | 0.020 |
Why?
|
| Disclosure | 1 | 2007 | 84 | 0.020 |
Why?
|
| North Carolina | 1 | 2006 | 130 | 0.020 |
Why?
|
| Europe | 1 | 2007 | 421 | 0.020 |
Why?
|
| Syndrome | 1 | 2007 | 381 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2006 | 82 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2008 | 224 | 0.010 |
Why?
|
| Lovastatin | 1 | 2006 | 37 | 0.010 |
Why?
|
| Protein Kinases | 1 | 1988 | 312 | 0.010 |
Why?
|
| Pravastatin | 1 | 2006 | 45 | 0.010 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2006 | 55 | 0.010 |
Why?
|
| Exercise Therapy | 1 | 2010 | 475 | 0.010 |
Why?
|
| Heptanoic Acids | 1 | 2006 | 67 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 282 | 0.010 |
Why?
|
| Hematocrit | 1 | 2005 | 108 | 0.010 |
Why?
|
| Midwestern United States | 1 | 2004 | 44 | 0.010 |
Why?
|
| Northwestern United States | 1 | 2004 | 58 | 0.010 |
Why?
|
| Pyrroles | 1 | 2006 | 220 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 770 | 0.010 |
Why?
|
| Diastole | 1 | 2004 | 146 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 2007 | 322 | 0.010 |
Why?
|
| Veterans | 1 | 2015 | 1642 | 0.010 |
Why?
|
| Social Support | 1 | 2007 | 651 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2003 | 405 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2004 | 421 | 0.010 |
Why?
|
| Indoles | 1 | 2006 | 507 | 0.010 |
Why?
|
| Pyridines | 1 | 2006 | 609 | 0.010 |
Why?
|
| Child | 2 | 2013 | 22739 | 0.010 |
Why?
|
| Counseling | 1 | 2004 | 401 | 0.010 |
Why?
|
| Neoplasms | 1 | 2015 | 2913 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 1999 | 125 | 0.010 |
Why?
|
| Endocarditis, Bacterial | 1 | 1999 | 46 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 1999 | 132 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2004 | 697 | 0.010 |
Why?
|
| Alcoholism | 1 | 2004 | 826 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2013 | 11868 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1999 | 1512 | 0.010 |
Why?
|
| Cystectomy | 1 | 1995 | 42 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 1995 | 70 | 0.010 |
Why?
|
| Prostatectomy | 1 | 1995 | 94 | 0.010 |
Why?
|
| Jejunostomy | 1 | 1994 | 14 | 0.010 |
Why?
|
| Image Enhancement | 1 | 1995 | 200 | 0.010 |
Why?
|
| Intestinal Fistula | 1 | 1994 | 18 | 0.010 |
Why?
|
| Bupivacaine | 1 | 1994 | 41 | 0.010 |
Why?
|
| Enteric Nervous System | 1 | 1994 | 26 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1995 | 508 | 0.010 |
Why?
|
| Dogs | 1 | 1994 | 478 | 0.010 |
Why?
|
| Nerve Block | 1 | 1994 | 108 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 1994 | 292 | 0.010 |
Why?
|
| Prostaglandins A | 1 | 1988 | 9 | 0.000 |
Why?
|
| Tocopherols | 1 | 1988 | 31 | 0.000 |
Why?
|
| Cyclic AMP | 1 | 1988 | 208 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1988 | 887 | 0.000 |
Why?
|
| Cell Survival | 1 | 1988 | 1103 | 0.000 |
Why?
|
| Animals | 2 | 1994 | 38097 | 0.000 |
Why?
|
| Mice | 1 | 1988 | 18355 | 0.000 |
Why?
|